首页> 外文OA文献 >Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results

【2h】

Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results

机译：基于ATAZANAVIR的高活性抗逆转录病毒治疗患者的疗效和安全性从稳定，提升或未加强的蛋白酶抑制剂治疗方案切换的病毒学抑制患者：天鹅研究（AI424-097）48周的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J. Gatell; D. S. Ceron; A. Lazzarin; E. V. Wijngaerden; F. Antunes; C. Leen; A. Horban; V. Wirtz; L. Odeshoo; M. V. d. Dungen; C. Gruber; E. Ledesma;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results [J] . Jose Gatell1 Dominique Salmon Ceron2 Adriano Lazzarin3 Eric Van Wijngaerden4 Francisco Antunes6 Clifford Leen7 Andrzej Horban8 Victoria Wirtz9 Linda Odeshoo9 Monique Van den Dungen5 Claudia Gruber5 Emilio Ledesma9a and SWAN Study Groupb Clinical Infectious Diseases . 2007,第11期

机译：从稳定，增强或未增强蛋白酶抑制剂治疗方案转向基于病毒抑制的Atazanavir高活性抗逆转录病毒疗法的疗效和安全性：SWAN研究（AI424-097）48周结果
2. SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed hiv-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen [J] . CampoR., DejesusE., BredeekU.F., Clinical infectious diseases . 2013,第11期

机译：SWIFT：一项为期48周的前瞻性研究，以评估在病毒抑制的hiv-1感染的患者中，使用含抗逆转录病毒疗法的加强型蛋白酶抑制剂，从拉米夫定/阿巴卡韦转用恩曲他滨/替诺福韦的疗效和安全性
3. SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed hiv-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen [J] . CampoR., DejesusE., BredeekU.F., Clinical infectious diseases . 2013,第11期

机译：SWIFT：预期48周的研究，评估从含有抗逆转录血液抑制剂的病毒学抑制的HIV-1感染患者中从拉米夫定/阿巴卡韦转向Emtricedabine / Tenofovir的疗效和安全性
4. Efficacy and Safety of Didanosine (ddI) and Tenofovir (TDF) Combination as NRTI Backbone of Highly Active Antiretrovirai Treatment (HAART). (24 wk Preliminary Results from Recover Study). [C] . M.J. Galindo, J. Lopez Aldeguer, M. Salavert International AIDS Conference . 2004

机译：脱蛋白（DDI）和替诺福韦（TDF）组合作为高活性抗逆转录（HAART）的NRTI骨架的疗效和安全性。（恢复研究中的24条WK初步结果）。
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen [O] . R. Campo, E. DeJesus, U. F. Bredeek, -1

机译：SWIFT：前瞻性48周研究评估了在病毒学抑制的HIV-1感染患者中使用抗逆转录病毒疗法增强的蛋白酶抑制剂后从拉米夫定/依巴韦星转用恩曲他滨/替诺福韦的疗效和安全性
7. Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：每周48个祖母绿的结果：第3期，随机的非劣升性研究，评估从增强蛋白酶抑制剂（BPI）加上的促蛋白（BPI）和替尼罗韦（FTC）/ Tenofovir Disoproxil umarate（TDF）方案的疗效和安全性对一次每日（QD ），在病毒学抑制的单片机/ Cobicistat / Emtricisabine / enftricitabine / Tenofovir Alafenainide（D / C / F / TAF）的单片植物（str），HIV-1感染的成年人

Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results

著录项

引文网络

相似文献

相关主题

期刊订阅